[Form 4] Charles River Laboratories International, Inc. Insider Trading Activity
Joseph W. LaPlume, an officer and director at Charles River Laboratories (CRL) serving as EVP, Corporate Strategy & Development, reported an open-market sale of 800 shares of CRL common stock on 08/18/2025 at a reported price of $157.60 per share. After the transaction he beneficially owned 24,116 shares. The Form 4 was signed on 08/20/2025. The filing discloses a single non-derivative sale and no derivatives or additional transactions.
Joseph W. LaPlume, dirigente e membro del consiglio di Charles River Laboratories (CRL) con la carica di EVP, Corporate Strategy & Development, ha segnalato una vendita in mercato aperto di 800 azioni ordinarie CRL effettuata il 18/08/2025 al prezzo indicato di $157,60 per azione. Dopo l鈥檕perazione deteneva utilmente 24.116 azioni. Il Modulo 4 猫 stato firmato il 20/08/2025. La documentazione indica una sola vendita non derivata e nessuna transazione derivata o ulteriore.
Joseph W. LaPlume, ejecutivo y miembro del consejo en Charles River Laboratories (CRL) que se desempe帽a como EVP, Corporate Strategy & Development, inform贸 una venta en mercado abierto de 800 acciones ordinarias de CRL el 18/08/2025 a un precio reportado de $157.60 por acci贸n. Tras la operaci贸n pose铆a beneficiosamente 24,116 acciones. El Formulario 4 fue firmado el 20/08/2025. La presentaci贸n revela una 煤nica venta no derivada y ninguna transacci贸n con derivados ni adicionales.
Joseph W. LaPlume電� Charles River Laboratories(CRL)鞐愳劀 EVP, Corporate Strategy & Development搿� 鞛 欷戩澑 鞛勳洂 瓴� 鞚挫偓搿滌劀 2025雲� 8鞗� 18鞚�鞐� CRL 氤错喌欤� 800欤�毳� 瓿店皽 鞁滌灔鞐愳劀 欤茧嫻 $157.60鞐� 毵る弰頄堧嫟瓿� 鞁犼碃頄堨姷雼堧嫟. 瓯半灅 頉� 攴鸽姅 鞁れ鞝侅溂搿� 24,116欤�毳� 氤挫湢頃橁碃 鞛堨棃鞀惦媹雼�. Form 4電� 2025雲� 8鞗� 20鞚�鞐� 靹滊獏霅橃棃鞀惦媹雼�. 鞝滌稖 靹滊鞐愲姅 雼澕 牍勴寣靸� 毵る弰毵� 瓿店皽霃� 鞛堨溂氅� 韺岇儩靸來拡鞚措倶 於旉皜 瓯半灅電� 鞐嗢姷雼堧嫟.
Joseph W. LaPlume, dirigeant et administrateur chez Charles River Laboratories (CRL) exer莽ant la fonction d'EVP, Corporate Strategy & Development, a d茅clar茅 une vente en march茅 ouvert de 800 actions ordinaires CRL le 18/08/2025 au prix d茅clar茅 de 157,60 $ par action. Apr猫s la transaction, il d茅tenait de mani猫re b茅n茅ficiaire 24 116 actions. Le formulaire 4 a 茅t茅 sign茅 le 20/08/2025. Le d茅p么t r茅v猫le une unique vente non d茅riv茅e et aucune op茅ration d茅riv茅e ou suppl茅mentaire.
Joseph W. LaPlume, Vorstand und Direktor bei Charles River Laboratories (CRL) in der Funktion als EVP, Corporate Strategy & Development, meldete am 18.08.2025 einen Verkauf von 800 Aktien der CRL-Stammaktien im offenen Markt zu einem gemeldeten Preis von $157,60 pro Aktie. Nach der Transaktion hielt er wirtschaftlich 24.116 Aktien. Das Formular 4 wurde am 20.08.2025 unterschrieben. Die Einreichung weist nur einen nicht-derivativen Verkauf aus; derivativen oder weiteren Transaktionen gab es nicht.
- None.
- Insider sale reported: Officer/director sold 800 shares at $157.60, reducing holdings to 24,116 shares.
Insights
TL;DR: Insider sold a small block of shares; transaction appears routine and provides limited new information for valuation.
The sale of 800 shares at $157.60 reduced the reporting person鈥檚 holdings to 24,116 shares. The filing contains only a single non-derivative sale and no derivative activity. Without additional context on pre-existing plans, size relative to total holdings, or timing rationale, this transaction is a routine disclosure and is unlikely to materially change the company鈥檚 financial outlook.
TL;DR: Officer/director sale documented properly on Form 4; disclosure meets Section 16 requirements.
The Form 4 indicates the reporting person is both an officer and director and shows the required signature and dates. The report lists the transaction code for a sale and specifies direct ownership. The filing contains no indication of Rule 10b5-1 plan or other exemptions. From a governance and compliance perspective, the document appears complete for the disclosed transaction.
Joseph W. LaPlume, dirigente e membro del consiglio di Charles River Laboratories (CRL) con la carica di EVP, Corporate Strategy & Development, ha segnalato una vendita in mercato aperto di 800 azioni ordinarie CRL effettuata il 18/08/2025 al prezzo indicato di $157,60 per azione. Dopo l鈥檕perazione deteneva utilmente 24.116 azioni. Il Modulo 4 猫 stato firmato il 20/08/2025. La documentazione indica una sola vendita non derivata e nessuna transazione derivata o ulteriore.
Joseph W. LaPlume, ejecutivo y miembro del consejo en Charles River Laboratories (CRL) que se desempe帽a como EVP, Corporate Strategy & Development, inform贸 una venta en mercado abierto de 800 acciones ordinarias de CRL el 18/08/2025 a un precio reportado de $157.60 por acci贸n. Tras la operaci贸n pose铆a beneficiosamente 24,116 acciones. El Formulario 4 fue firmado el 20/08/2025. La presentaci贸n revela una 煤nica venta no derivada y ninguna transacci贸n con derivados ni adicionales.
Joseph W. LaPlume電� Charles River Laboratories(CRL)鞐愳劀 EVP, Corporate Strategy & Development搿� 鞛 欷戩澑 鞛勳洂 瓴� 鞚挫偓搿滌劀 2025雲� 8鞗� 18鞚�鞐� CRL 氤错喌欤� 800欤�毳� 瓿店皽 鞁滌灔鞐愳劀 欤茧嫻 $157.60鞐� 毵る弰頄堧嫟瓿� 鞁犼碃頄堨姷雼堧嫟. 瓯半灅 頉� 攴鸽姅 鞁れ鞝侅溂搿� 24,116欤�毳� 氤挫湢頃橁碃 鞛堨棃鞀惦媹雼�. Form 4電� 2025雲� 8鞗� 20鞚�鞐� 靹滊獏霅橃棃鞀惦媹雼�. 鞝滌稖 靹滊鞐愲姅 雼澕 牍勴寣靸� 毵る弰毵� 瓿店皽霃� 鞛堨溂氅� 韺岇儩靸來拡鞚措倶 於旉皜 瓯半灅電� 鞐嗢姷雼堧嫟.
Joseph W. LaPlume, dirigeant et administrateur chez Charles River Laboratories (CRL) exer莽ant la fonction d'EVP, Corporate Strategy & Development, a d茅clar茅 une vente en march茅 ouvert de 800 actions ordinaires CRL le 18/08/2025 au prix d茅clar茅 de 157,60 $ par action. Apr猫s la transaction, il d茅tenait de mani猫re b茅n茅ficiaire 24 116 actions. Le formulaire 4 a 茅t茅 sign茅 le 20/08/2025. Le d茅p么t r茅v猫le une unique vente non d茅riv茅e et aucune op茅ration d茅riv茅e ou suppl茅mentaire.
Joseph W. LaPlume, Vorstand und Direktor bei Charles River Laboratories (CRL) in der Funktion als EVP, Corporate Strategy & Development, meldete am 18.08.2025 einen Verkauf von 800 Aktien der CRL-Stammaktien im offenen Markt zu einem gemeldeten Preis von $157,60 pro Aktie. Nach der Transaktion hielt er wirtschaftlich 24.116 Aktien. Das Formular 4 wurde am 20.08.2025 unterschrieben. Die Einreichung weist nur einen nicht-derivativen Verkauf aus; derivativen oder weiteren Transaktionen gab es nicht.
FAQ
What did Joseph W. LaPlume report on the Form 4 for CRL?
What is Joseph W. LaPlume's role at Charles River Laboratories (CRL)?
When was the Form 4 for this transaction signed?
Does the filing show any derivative transactions or 10b5-1 plan?
